CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

Published Date: 18 Mar 2024

For CLL/SLL patients who are refractory or have relapsed, lixocabtagene maraleucel (Breyanzi) has a new indication.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

2.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.

3.

Base Treatment Decisions in Metastatic Breast Cancer on Presence of ESR1 Mutations

4.

Elder Abuse: Red Flags to Look Out For While Receiving Care.

5.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot